Literature DB >> 24374956

Upregulation of mitogen-activated protein kinase in ganglioglioma.

Beata Rak1, Stanisław Szlufik, Wiesława Grajkowska, Danuta Perek, Bożena Dembowska-Bagińska, Iwona Filipek, Paweł Daszkiewicz, Paweł Włodarski, Jarosław Jóźwiak.   

Abstract

Ganglioglioma (GG) is a low-grade neoplasm, often associated with intractable epilepsy in pediatric patients. Available data suggest a relationship between GG and other glioneuronal lesions. So far, little is known about activation of kinases belonging to the mTor (mammalian target of rapamycin) pathway, although its upregulation is often found in brain tumors. Involvement of mTor kinase is responsible for excessive proliferation. In the current study we focused on the possible role of the Erk/Mapk (extracellular-signal-regulated kinase/mitogen-activated protein kinase) pathway in GG development. Eight GG tumors were resected from pediatric patients. Collected data reveal activation of proteins from the Erk pathway: Mek (extracellular regulated protein kinase kinase/mitogen-activated protein kinase kinase), Erk, Rsk1 (ribosomal S6 kinase 1), Rheb (Ras homolog enriched in brain) and Msk1 (mitogen- and stress-activated protein kinase 1), as detected by the western blot method. Moreover, activation of other proteins upstream of mTor - IGF-1R β (insulin-like growth factor 1β receptor), INR β (insulin receptor β), Akt/PKB (protein kinase B) - or downstream - 4E-BP1 (eukaryotic translation initiation factor 4E-binding protein 1) and rpS6 (ribosomal protein S6) - was also confirmed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24374956     DOI: 10.5114/fn.2013.39717

Source DB:  PubMed          Journal:  Folia Neuropathol        ISSN: 1509-572X            Impact factor:   2.038


  2 in total

1.  Cerebellar Ganglioglioma in Childhood: Histopathologic Implications for Management During Long-term Survival: A Case Report.

Authors:  Koyo Ohno; Yoshiaki Saito; Akiko Tamasaki-Kondo; Atsushi Kambe; Yasushi Horie; Shinsuke Kato; Yoshihiro Maegaki
Journal:  Yonago Acta Med       Date:  2018-02-05       Impact factor: 1.641

2.  Heterogeneity and excitability of BRAFV600E-induced tumors is determined by Akt/mTOR-signaling state and Trp53-loss.

Authors:  Silvia Cases-Cunillera; Karen M J van Loo; Julika Pitsch; Anne Quatraccioni; Sugirthan Sivalingam; Paolo Salomoni; Valeri Borger; Dirk Dietrich; Susanne Schoch; Albert J Becker
Journal:  Neuro Oncol       Date:  2022-05-04       Impact factor: 13.029

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.